Factors that influence prescribing within a therapeutic drug class

Journal of Evaluation in Clinical Practice

Volumn 11, Issue 4, 2005, Pages 357-365

  Nutescu, Edith A ^a   Park, Hayley Y ^a   Walton, Surrey M ^a   Blackburn, Juan C ^a   Finley, Jamie M ^b   Lewis, Richard K ^c   Schumock, Glen T ^a,d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Mercy Resource Management Inc   (United States)

^c Pharmacy Services   (United States)

^d MRMI ^*  (United States)

Author keywords

Anticoagulants; Low molecular weight heparins; Pharmaceuticals; Physician behaviour; Prescribing

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; COMMUNITY HOSPITAL; DRUG USE; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; PHARMACIST; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RANK SUM TEST; UNITED STATES;

CHOICE BEHAVIOR; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALS, COMMUNITY; HUMANS; PHARMACISTS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; UNITED STATES;

EID: 23044434070     PISSN: 13561294     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2005.00545.x     Document Type: Article

References (26)

1. Bollinger K.A., Vermeulen L.C., Davis S.N. & Geurkink E.A. (2000) Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange. American Journal of Health-System Pharmacy 57 (4), 368-372.
2. Denig P., Haaijer-Ruskamp F.M. & Zijsling D.H. (1988) How physicians choose drugs. Social Science and Medicine 27, 381-1386.
3. Gainor C., Vanscoy G.J., Niccolai C.S. & Rihn T.L. (2003) Pharmacologic and liability considerations of therapeutic interchange with low-molecular-weight heparins. Hospital Pharmacy 38 (7), 652-658.
4. Garattini S. (1997) Are me-too drugs justified? Journal of Nephrology 10 (6), 283-294.
5. Jaccard J. & Wan C.K. (1996) LISREL Approaches to Interaction Effects in Multiple Regression. Sage Publications, Thousand Oaks, CA.
6. Jones M.I., Greenfield S.M. & Bradley C.P. (2001) Prescribing new drugs: qualitative study of influences on consultants and general practitioners. British Medical Journal 323, 378-381.
7. Kerlinger F. (1986) Foundations of Behavioral Research, 3rd edn. Holt, Rinehart and Winston, Inc., Fort Worth, TX.
8. McAlister F.A., Laupacis A., Wells G.A. & Sackett D.L. (1999) Users' guides to the medical literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. Journal of American Medical Association 282, 1371-1377.
9. Michalis L.K., Katsouras C.S., Papamichael N., Adamides K., Naka K.K., Goudevenos J. & Sideris D.A. (2003) Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. American Heart Journal 146 (2), 304-310.
10. Montalescot G., Bal-dit-Sollier C., Chibedi D. et al. (2003) Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). American Journal of Cardiology 91, 925-930.
11. National Institute for Health Care Management Foundation (2003) Changing Patterns of Pharmaceutical Innovation. National Institute for Health Care Management, Washington, DC.
12. Ozdemir M., Erdem G., Turkogly S., Cemri M., Timurkayanak T., Boyaci B., Ridvan Y., Cengel A., Dortlemezo O. & Dortlemezo H. (2002) Head-to-head comparison of two different low-molecular-weight heparins in acute coronary syndromes. A single center experience. Japanese Heart Journal 43, 433-442.
13. Planes A., Samama M.M., Lensing A.W., Buller H.R., Barre J., Vochelle N. & Beau B. (1999) Prevention of deep vein thrombosis after hip replacement - comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thrombosis and Haemostasis 81, 22-25.
14. Planes A., Vochelle N., Fagola M. & Bellaud M. (1998) Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group. Blood Coagulation and Fibrinolysis 9, 499-505.
15. Prosser H., Almond S. & Walley T. (2003) Influences on GPs' decision to prescribe new drugs-the importance of who says what. Family Practice 20 (1), 61-68.
16. Racine E. (2001) Differentiation of the low-molecular-weight heparins. Pharmacotherapy 21, 62S-70S.
17. Raisch D.W. (1990) A model of methods for influencing prescribing: Part II. A review of educational methods, theories of human inference, and delineation of the model. Drug Intelligence and Clinical Pharmacy 24, 537-542.
18. Rich D.S. (1989) Experience with a two-tiered therapeutic interchange policy. American Journal of Hospital Pharmacy 46, 1792-1798.
19. Schumock G.T., Nutescu E.A., Walton S.M., Arondekar B.V. & Lewis R.K. (2002) Survey of hospital policies regarding low-molecular-weight heparins. American Journal of Health System Pharmacy 59, 534-538.
20. Schumock G.T., Walton S.M., Park H.Y., Nutescu E.A., Blackburn J.C., Finley J.M. & Lewis R.K. (2004) Factors that influence prescribing decisions. Annals of Pharmacotherapy 38, 649-660.
21. Schwartz R.K., Soumerai S.B. & Avorn J. (1989) Physician motivations for nonscientific drug prescribing. Social Science and Medicine 28, 577-582.
22. Segal R. & Hepler C.D. (1982) Prescribes' beliefs and values as predictors of drug choices. American Journal of Hospital Pharmacy 39, 1891-1897.
23. Segal R. & Hepler C.D. (1985) Drug choice as a problem-solving process. Medical Care 23, 967-976.
24. Steinman M.A., Shlipak M.G. & McPhee S.J. (2001) Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. American Journal of Medicine 110 (7), 551-557.
25. US Bureau of the Census (1998) State and Metropolitan Area Data Book 1997-98, 5th edn. U.S. Bureau of the Census, Washington, DC.
26. Zelnio R.N. (1982) The interaction among the criteria physicians use when prescribing. Medical Care 20 (3), 277-285.